Want to see AU:RGT full AI Analyst Report?
RGT Stock Chart & Stats
AU$0.08
>-AU$0.01(-2.00%)
At close: 4:00 PM EST
AU$0.08
>-AU$0.01(-2.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.32
Previous CloseN/A
Volume362.25K
Average Volume (3M)77.74K
Market Cap
AU$4.11M
Enterprise ValueAU$10.41M
Total Cash (Recent Filing)AU$1.02M
Total Debt (Recent Filing)AU$8.29M
Price to Earnings (P/E)―
Beta-0.89
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding111,109,580
10 Day Avg. Volume131,422
30 Day Avg. Volume77,736
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.54
Price to Sales (P/S)7.94
P/FCF Ratio-0.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin ImprovementMaterial gross-margin improvement in 2025 suggests better product mix or pricing power; if maintained this boosts operating leverage and the ability to convert revenue into gross profit. Sustained higher gross margins make profitable scale or smaller break-even revenue more achievable over months.
Very Lean HeadcountAn extremely small workforce implies a low fixed cost base and operational flexibility. A lean structure reduces recurring payroll burden and enables quicker pivots or outsourcing, lowering near-term cash runway pressure and making cost reductions easier to sustain over several months.
Position In Specialty & Generic DrugsOperating in specialty and generic drug manufacturing aligns with durable market demand for off-patent and niche therapies. Structural needs for generics and specialty supply create recurring revenue opportunities and potential contract or licensing partnerships that can stabilize revenue over the medium term.
Bears Say
Negative Shareholders' EquityNegative equity across multiple years reflects cumulative losses that materially weaken the balance sheet and limit financial flexibility. This condition raises insolvency and refinancing risk, constrains access to non-dilutive capital, and is a persistent headwind until equity is rebuilt or restructured.
Persistent Heavy Cash BurnZero reported operating cash flow and multi-year negative free cash flow indicate ongoing reliance on external funding to run operations. Continued cash burn forces dilutive financing or asset sales, raising survival and execution risk unless management secures durable financing or rapidly alters the cost structure.
Sharp Revenue Contraction And LossesSteep, multi-year revenue declines paired with large operating losses show the company has lost scale and commercial traction. Smaller revenue magnifies fixed-cost strain, weakens margins, and makes profitable recovery challenging without new products, market re-entry, or structural commercial improvements.
Argent Biopharma News
RGT FAQ
What was Argent Biopharma’s price range in the past 12 months?
Argent Biopharma lowest share price was AU$0.03 and its highest was AU$0.32 in the past 12 months.
What is Argent Biopharma’s market cap?
Argent Biopharma’s market cap is AU$4.11M.
When is Argent Biopharma’s upcoming earnings report date?
Argent Biopharma’s upcoming earnings report date is Aug 28, 2026 which is in 60 days.
How were Argent Biopharma’s earnings last quarter?
Argent Biopharma released its earnings results on Feb 27, 2026. The company reported -AU$0.038 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.038.
Is Argent Biopharma overvalued?
According to Wall Street analysts Argent Biopharma’s price is currently Overvalued.
Does Argent Biopharma pay dividends?
Argent Biopharma does not currently pay dividends.
What is Argent Biopharma’s EPS estimate?
Argent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argent Biopharma have?
Argent Biopharma has 111,109,580 shares outstanding.
What happened to Argent Biopharma’s price movement after its last earnings report?
Argent Biopharma reported an EPS of -AU$0.038 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Argent Biopharma?
Currently, no hedge funds are holding shares in AU:RGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.17%
12-Months-Change
Fundamentals
Return on Equity
182.89%
Trailing 12-Months
Asset Growth
-29.21%
Trailing 12-Months
Company Description
Argent Biopharma
Argent BioPharma Limited, an Australian-headquartered biopharmaceutical firm founded in 2014, operates as a clinical-stage entity focused on developing innovative nano-engineered therapeutics. The company's core mission involves crafting treatments designed to re-establish a healthy balance between the nervous and immune systems, with its reach extending internationally to locations including Malta and Slovenia. Its diverse pipeline of product candidates is progressing through various clinical phases. CimetrA, a leading contender, is currently in Phase III trials targeting acute lung injury and Acute Respiratory Distress Syndrome (ARDS). For refractory epilepsy, CannEpil is undergoing Phase I clinical evaluation. Additionally, CogniCann is advancing through Phase IIA trials, aiming to offer symptomatic relief for Dementia and Alzheimer's disease. Beyond these clinical programs, Argent BioPharma is actively involved in the preclinical development of Irnican for Glioblastoma Multiforme and dedicates research and development efforts to wound treatment. The company has also forged a strategic partnership with SINTEF to enhance antimicrobial solutions for chronic wounds and explore potential applications in oncologic wound care. Previously known as MGC Pharmaceuticals Limited, the company officially rebranded to Argent BioPharma Limited.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―
Options Prices
Currently, No data available
---